Terms and Conditions

Welcome to the ANTHIM® (obiltoxaximab) Web site (www.anthim.com). Please read these terms and conditions carefully before accessing any pages of this Web site.

Your access to and use of this site is subject to the following terms and conditions and all applicable laws. By accessing and browsing this site, you accept, without limitation or qualification, these terms and conditions. If you do not agree to these terms and conditions, you may not access or use this site.

Information on this Web site is intended for general informational and educational purposes only. The information displayed or distributed through the Web site may contain general information relating to medical conditions and their treatment, but the information shall not be considered medical advice and shall not be relied upon as medical advice. Such information is for informational purposes only and you should consult with your physician for your medical needs.

You may only access, download, or use information from this site for your own non-commercial use. You may not distribute, modify, transmit, reuse, repost, or use the information for commercial purposes without written permission of Elusys Therapeutics, Inc.

You represent and warrant that you will not upload, post, transmit, distribute, or otherwise publish through the Web site any materials: that restrict or limit any other individual from using the Web site; are unlawful, threatening, abusive, defamatory, obscene, or indecent; constitute conduct that would be considered a criminal offense; violate the rights of any third parties, including, without limitation, their intellectual property rights; contain a virus or other harmful component; or that contain advertising. Moreover, you shall not use this Web site for any purpose, reason, or manner that would violate local, state, federal, or foreign law or regulation.

While Elusys Therapeutics, Inc. uses reasonable efforts to ensure that the information on this site is accurate, complete, and current, it may contain technical inaccuracies or typographical errors. Elusys Therapeutics, Inc. makes no warranties or representations as to the timeliness, completeness, or accuracy of any of the information on this Web site and assumes no liability or responsibility for any errors or omissions in the content of the site. All information provided on this Web site is provided "As Is" and at your own risk.

Elusys Therapeutics, Inc. reserves the right to make changes, corrections, and/or improvements to the information at any time without notice. You acknowledge and agree that your use and reliance upon any of the information contained on the Web site is at your risk. Elusys Therapeutics, Inc. does not have a duty to correct any errors or omissions in any portion of the Web site but reserves the rights to make such corrections at any time.

Neither Elusys Therapeutics, Inc. nor any other party involved in creating, producing, or delivering this Web site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of access to, use of, or inability to use this site, or any errors or omissions in the content of the site. In no event shall Elusys Therapeutics, Inc. have any liability to you for any damages, losses, or causes of action. This limitation includes, but is not limited to, damages to, or for any viruses that infect, your computer equipment. Use of the Web site is completely at your own risk.

You agree to indemnify Elusys Therapeutics, Inc., its officers, employees, owners, representatives, agents, subsidiaries, affiliates, officers, partners, suppliers, and licensors (hereinafter individually and collectively referred to as "Indemnitees") and Elusys Therapeutics, Inc. agrees to control any litigation, negotiations, discussions, settlements, or associated dealings, for any claims, demands, penalties, fines, liabilities, attorneys' fees, court costs, legal expenses, and causes of action of any nature, whether civil or criminal, for losses and/or damages of any kind which may be brought against Elusys Therapeutics, Inc. and/or Indemnitees, in any way, directly or indirectly, incident to, arising out of, in connection with or resulting from your use of or inability to use the Web site.

Notwithstanding any provision to the contrary, this Agreement and the interpretation of its terms shall be governed and construed in accordance with the laws of the State of New Jersey, without regard to its conflicts of laws rules. The parties consent to the sole and exclusive jurisdiction and venue of the New Jersey state courts for all state court matters, and the United States District Court for the District of New Jersey for all federal court matters.

Links to third-party sites may be provided for your interest or convenience. However, Elusys Therapeutics, Inc. has no control over the statements, products, or services featured or sold at third-party sites. Elusys Therapeutics, Inc. accepts no liability for links to others; in particular, we are not responsible for the accuracy or legality of the content thereof. We accept no liability deriving from a breach or omission in the privacy policies of third parties. Links to third-party sites do not constitute an endorsement by Elusys Therapeutics, Inc. of the third-party sites, nor any of the statements, products, or services offered or sold at the third-party sites. We recommend that you review the Terms and Conditions/Legal Statements of any sites that you visit.

This Web site is protected by copyright pursuant to U.S. copyright laws, international conventions, and other copyright laws. The contents of the Web site are only for your personal, noncommercial use. All materials contained on the Web site are protected by copyright and are owned or controlled by Elusys Therapeutics, Inc. or the party credited as the provider of the content. You agree to abide by any and all additional copyright notices, information, or restrictions contained in any part of the Web site. Copying or storing of any content from the Web site is expressly prohibited without prior written permission from Elusys Therapeutics, Inc. or the copyright holder as identified on the Web site.

You agree not to delete any trademark or similar notice owned by Elusys Therapeutics, Inc. from any contents that you obtain from the Web site. Any questions concerning the use of trademarks should be referred to Elusys Therapeutics, Inc. All trademarks mentioned in the Web site belong to Elusys Therapeutics, Inc. or one of its related companies unless designated otherwise. You agree not to use any trademarks without the prior written permission from Elusys Therapeutics, Inc.

Elusys Therapeutics, Inc. may change, suspend, or discontinue any aspect of the Web site at any time. Elusys Therapeutics, Inc. may also impose limits on certain features and services or restrict access to parts or all of the Web site without notice or liability.

The contents of this Web site are intended to comply with Unites States laws and regulations. Although the information on this Web site may be accessible to users outside of the United States, the information pertaining to Elusys Therapeutics, Inc.’s products is intended for use solely by residents of the United States. Other countries may have laws, regulatory requirements, and medical practices that differ from those in the United States. Elusys Therapeutics, Inc. reserves the right to limit provision of its products or services to any person, geographic region, or jurisdiction and/or to limit the quantities of any products or services we provide. Any offer for any product or service made on this Web site is void where prohibited.

Please see our Privacy Policy for information regarding the collection and use of personal information from this Web site.

Elusys Therapeutics, Inc. may revise these terms and conditions by updating this posting at any time. You are bound by any such revisions and should therefore periodically visit this page to review the then current terms and conditions to which you are bound.

If you wish to contact us regarding these Terms and Conditions, please e-mail us at info@elusys.com.



ANTHIM® (obiltoxaximab) is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. ANTHIM is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate.


  • ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of serious hypersensitivity reactions and anaphylaxis.
  • The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax.
  • Safety and PK of ANTHIM have been studied in adult healthy volunteers. There have been no studies of safety or PK of ANTHIM in the pediatric population. A population PK approach was used to derive intravenous infusion dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults.
  • ANTHIM binds to the protective antigen (PA) component of B. anthracis toxin; it does not have direct antibacterial activity. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis. ANTHIM should be used in combination with appropriate antibacterial drugs.



Hypersensitivity and anaphylaxis have been reported during the intravenous infusion of ANTHIM. Due to the risk of hypersensitivity and anaphylaxis, ANTHIM should be administered in monitored settings by personnel trained and equipped to manage anaphylaxis. Monitor individuals who receive ANTHIM closely for signs and symptoms of hypersensitivity reactions throughout the infusion and for a period of time after administration. Stop ANTHIM infusion immediately and treat appropriately if hypersensitivity or anaphylaxis occurs.


Hypersensitivity reactions were the most common adverse reactions in the safety trials of ANTHIM, occurring in 34/320 healthy subjects (10.6%). Three (0.9%) cases of anaphylaxis occurred during or immediately after the infusion. In clinical trials, manifestations of anaphylaxis were rash/urticaria, cough, dyspnea, cyanosis, postural dizziness and chest discomfort. ANTHIM infusion was discontinued in 8 (2.5%) subjects due to hypersensitivity or anaphylaxis. The adverse reactions reported in these 8 subjects included urticaria, rash, cough, pruritus, dizziness, throat irritation, dysphonia, dyspnea and chest discomfort. The remaining subjects with hypersensitivity had predominantly skin-related symptoms such as pruritus and rash, and 6 subjects reported cough.

Premedication with diphenhydramine is recommended prior to administration of ANTHIM. Diphenhydramine premedication does not prevent anaphylaxis, and may mask or delay onset of symptoms of hypersensitivity.


The safety of ANTHIM has been studied only in healthy volunteers. It has not been studied in patients with inhalational anthrax. The most frequently reported adverse reactions (occurred in >1.5% of healthy subjects) were headache, pruritus, infections of the upper respiratory tract, cough, vessel puncture site bruise, infusion site swelling, urticaria, nasal congestion, infusion site pain, and pain in extremity.


No adequate and well-controlled studies in pregnant women were conducted. Because animal reproduction studies are not always predictive of human response, ANTHIM should be used during pregnancy only if clearly needed.

Pediatric Use
There have been no studies of the safety or PK of ANTHIM in the pediatric population.

To see the complete prescribing information for ANTHIM, click here.